MEDI-PHYSICS
SpecialtyMEDI-PHYSICS is a specialty pharmaceutical company focused on Cardiovascular, Oncology.
MEDI-PHYSICS's Key Drugs
MEDI-PHYSICS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
MEDI-PHYSICS's Recent FDA Approvals
New NDA/BLA approvals for MEDI-PHYSICS over the last two years — novel drugs only, excluding generics and label supplements.
MEDI-PHYSICS's Therapeutic Areas
MEDI-PHYSICS's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Oncology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MEDI-PHYSICS's Top Competitors
MEDI-PHYSICS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MEDI-PHYSICS Pipeline Snapshot
MEDI-PHYSICS has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1996-02-09
- Latest
- 2022-12-06
- Applications
- 1